Quanome to Issue 6.54M Shares (~16% Dilution) for 5% Stake in QAI Labs
QNME sits 60% above its 52-week low of $0.25.
Summary
Quanome agreed to issue 6,541,236 new shares — about 16% of its post-deal share count — for a ~5% stake in early-stage QAI Labs, valuing the target at roughly US$100 million. The all-stock deal is signed but not closed and adds dilution on top of an existing going-concern and Nasdaq bid-price problem.
Key Events · M&A and Partnerships · QNME
-
All-Stock Deal for 5% of QAI Labs
Quanome will acquire 31,579 newly issued QAI Labs shares, representing approximately 5% of the target, in exchange for 6,541,236 newly issued Quanome common shares.
-
Roughly 16% Dilution to Quanome Holders
The new shares equal about 19% of Quanome's outstanding common stock immediately before issuance and about 15.97% immediately after, per the press release.
-
US$5.0M Consideration, ~US$100M Target Valuation
The parties assigned the consideration shares an aggregate negotiated value of US$5.0 million, implying an approximately US$100 million equity valuation for QAI Labs based on the stake acquired.
-
Target Is Pre-Commercial With No IND Studies
QAI Labs' NOVA-3 platform is early-stage; its two in-licensed programs are preclinical and no IND-enabling studies have commenced, so any commercial payoff is years away and unproven.
Analysis · QNME · Energy & Transportation
Quanome is paying with its own stock rather than cash: 6,541,236 new shares — roughly 16% of the post-issuance share count — buys only a ~5% minority stake in a pre-commercial antibody-discovery startup with no approved products and no IND-enabling studies started. The company assigned the consideration a US$5.0 million value, implying a ~US$100 million valuation for QAI Labs, a figure that rests on a third-party appraisal of an early-stage platform rather than revenue or clinical data. For a company that already carries a going-concern warning and a Nasdaq minimum-bid deficiency, adding equity dilution to fund a speculative life-sciences pivot is a real cost to existing holders, and the deal is not yet closed — it still needs consents, Nasdaq listing review and satisfaction of closing conditions by December 31, 2026.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNME was trading at $0.40 on NASDAQ in the Energy & Transportation sector, with a market capitalization of approximately $12.8M. The 52-week trading range was $0.25 to $1.40. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.